These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 29516279

  • 1. Eculizumab reversed severe distal ischemic syndrome and glomerulonephritis with isolated C3 deposits associated with anti-factor H autoantibodies: a case report.
    Deshayes S, Martin Silva N, Chatelet V, Chantepie S, Le Quintrec M, Comoz F, Bridoux F, Dragon-Durey MA, Aouba A.
    Clin Rheumatol; 2018 Apr; 37(4):1119-1122. PubMed ID: 29516279
    [Abstract] [Full Text] [Related]

  • 2. Blockade of C5 in Severe Acute Postinfectious Glomerulonephritis Associated With Anti-Factor H Autoantibody.
    Chehade H, Rotman S, Frémeaux-Bacchi V, Aubert V, Sadallah S, Sifaki L, Salomon R, Pascual M.
    Am J Kidney Dis; 2016 Dec; 68(6):944-948. PubMed ID: 27683044
    [Abstract] [Full Text] [Related]

  • 3. A case of C3 glomerulonephritis successfully treated with eculizumab.
    Payette A, Patey N, Dragon-Durey MA, Frémeaux-Bacchi V, Le Deist F, Lapeyraque AL.
    Pediatr Nephrol; 2015 Jun; 30(6):1033-7. PubMed ID: 25796589
    [Abstract] [Full Text] [Related]

  • 4. C3 glomerulonephritis secondary to mutations in factors H and I: rapid recurrence in deceased donor kidney transplant effectively treated with eculizumab.
    Garg N, Zhang Y, Nicholson-Weller A, Khankin EV, Borsa NG, Meyer NC, McDermott S, Stillman IE, Rennke HG, Smith RJ, Pavlakis M.
    Nephrol Dial Transplant; 2018 Dec 01; 33(12):2260-2265. PubMed ID: 29370420
    [Abstract] [Full Text] [Related]

  • 5. Anti-complement-factor H-associated glomerulopathies.
    Durey MA, Sinha A, Togarsimalemath SK, Bagga A.
    Nat Rev Nephrol; 2016 Sep 01; 12(9):563-78. PubMed ID: 27452363
    [Abstract] [Full Text] [Related]

  • 6. C3 glomerulopathy: A new complement-based entity.
    de Lorenzo A, Tallón S, Hernández-Sevillano B, de Arriba G.
    Rev Clin Esp (Barc); 2014 Sep 01; 214(5):266-74. PubMed ID: 24576419
    [Abstract] [Full Text] [Related]

  • 7. Treatment of C3 glomerulopathy with complement blockers.
    Vivarelli M, Emma F.
    Semin Thromb Hemost; 2014 Jun 01; 40(4):472-7. PubMed ID: 24799307
    [Abstract] [Full Text] [Related]

  • 8. C3 glomerulonephritis and systemic lupus erythematosus: A report of a patient treated with eculizumab and review of the literature.
    Fernandez-Ruiz R, Blank RB, Wu M, Belmont HM.
    Lupus; 2021 Sep 01; 30(10):1671-1678. PubMed ID: 34192954
    [Abstract] [Full Text] [Related]

  • 9. Eculizumab in post-transplant C3 glomerulonephritis caused by a C3 mutation
.
    Kim JS, Foster KW, Westphal SG.
    Clin Nephrol; 2020 Jan 01; 93(1):51-56. PubMed ID: 31661064
    [Abstract] [Full Text] [Related]

  • 10. Pathology after eculizumab in dense deposit disease and C3 GN.
    Herlitz LC, Bomback AS, Markowitz GS, Stokes MB, Smith RN, Colvin RB, Appel GB, D'Agati VD.
    J Am Soc Nephrol; 2012 Jul 01; 23(7):1229-37. PubMed ID: 22677550
    [Abstract] [Full Text] [Related]

  • 11. Severe active C3 glomerulonephritis triggered by immune complexes and inactivated after eculizumab therapy.
    Kersnik Levart T, Ferluga D, Vizjak A, Mraz J, Kojc N.
    Diagn Pathol; 2016 Oct 07; 11(1):94. PubMed ID: 27717365
    [Abstract] [Full Text] [Related]

  • 12. Anti-complement therapy for glomerular diseases.
    Bomback AS.
    Adv Chronic Kidney Dis; 2014 Mar 07; 21(2):152-8. PubMed ID: 24602464
    [Abstract] [Full Text] [Related]

  • 13. Treating C3 glomerulopathy with eculizumab.
    Welte T, Arnold F, Kappes J, Seidl M, Häffner K, Bergmann C, Walz G, Neumann-Haefelin E.
    BMC Nephrol; 2018 Jan 12; 19(1):7. PubMed ID: 29329521
    [Abstract] [Full Text] [Related]

  • 14. Eculizumab in anti-factor h antibodies associated with atypical hemolytic uremic syndrome.
    Diamante Chiodini B, Davin JC, Corazza F, Khaldi K, Dahan K, Ismaili K, Adams B.
    Pediatrics; 2014 Jun 12; 133(6):e1764-8. PubMed ID: 24843055
    [Abstract] [Full Text] [Related]

  • 15. Discontinuation of dialysis with eculizumab therapy in a pediatric patient with dense deposit disease.
    Tran CL, Sethi S, Murray D, Cramer CH, Sas DJ, Willrich M, Smith RJ, Fervenza FC.
    Pediatr Nephrol; 2016 Apr 12; 31(4):683-7. PubMed ID: 26759144
    [Abstract] [Full Text] [Related]

  • 16. Patterns of Clinical Response to Eculizumab in Patients With C3 Glomerulopathy.
    Le Quintrec M, Lapeyraque AL, Lionet A, Sellier-Leclerc AL, Delmas Y, Baudouin V, Daugas E, Decramer S, Tricot L, Cailliez M, Dubot P, Servais A, Mourey-Epron C, Pourcine F, Loirat C, Frémeaux-Bacchi V, Fakhouri F.
    Am J Kidney Dis; 2018 Jul 12; 72(1):84-92. PubMed ID: 29429752
    [Abstract] [Full Text] [Related]

  • 17. [C3 glomerulopathy].
    Rollino C.
    G Ital Nefrol; 2014 Jul 12; 31(1):. PubMed ID: 24671835
    [Abstract] [Full Text] [Related]

  • 18. Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders.
    Wehling C, Amon O, Bommer M, Hoppe B, Kentouche K, Schalk G, Weimer R, Wiesener M, Hohenstein B, Tönshoff B, Büscher R, Fehrenbach H, Gök ÖN, Kirschfink M.
    Clin Exp Immunol; 2017 Feb 12; 187(2):304-315. PubMed ID: 27784126
    [Abstract] [Full Text] [Related]

  • 19. Histopathology of MPGN and C3 glomerulopathies.
    Cook HT, Pickering MC.
    Nat Rev Nephrol; 2015 Jan 12; 11(1):14-22. PubMed ID: 25447133
    [Abstract] [Full Text] [Related]

  • 20. Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases.
    Nester CM, Brophy PD.
    Curr Opin Pediatr; 2013 Apr 12; 25(2):225-31. PubMed ID: 23486421
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.